Nasdaq Biotechnology Ishares ETF (IBB)
$120.63 0.34 (0.28%)
19:14 EST IBB Stock Quote Delayed 15 Minutes
Previous Close $120.63
Market Cap 10.49B
PE Ratio -
Volume (Avg. Vol.) 2.85M
Day's Range 119.89 - 122.00
52-Week Range 89.01 - 122.00
Dividend & Yield 0.31 (0.26%)
IBB Stock Predictions, Articles, and Nasdaq Biotechnology Ishares ETF News
- From InvestorPlace
- From the Web
This morning, I'm recommending a bullish call option on Aimmune Therapeutics, Inc. (NASDAQ:AIMT), the biopharmaceutical company.
Bitcoin, Biotech, Micron and Starbucks were our top stock trades to watch. Here's how the charts are setting up going into Friday.
Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.
Investors turned sour on BMY stock after the Celgene buyout. Will a solid Q2 earnings report change the sentiment for the better?
Memory stocks like Micron and semiconductor stocks like AMD were on the move in the Nasdaq today. Intel and Cisco weren't so lucky though.
Netflix, IBM, Abbott Labs, Domino's Pizza and the IBB ETF were our top stock trades to watch for Thursday, the last trading day this week.
AZN stock is great to own, but you should choose your entry points carefully, as AstraZeneca has some short-term risks ahead.
Regardless of political risks, there are still valuable opportunities in some healthcare stocks. Here are three to consider.
The charts for the IBB ETF in multiple time frames suggest the recent rally in biotech stocks is overdone for the time being.
This morning I am recommending a bearish trade on the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).
This morning I am recommending a bullish trade on the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB). I like the biotech sector, and it has generally been holding up well during the recent volatility.
Gilead stock is cheap selling at 11 price-earnings ratio. And it's coming into a long-term support zone. Catch the falling butter knife.
Pfizer renewed the drug price hike cycle after it raised them for around 40 products. If other biotech stocks follow, profits will soar.
PFE is a proven survivor stock and it now sits on a potential long term technical breakout. Go long its potential with confidence.
Large-cap biotech stocks as a group rallied along with the broader stock market on Wednesday. While so doing, some big names like AMGN stock broke past key near-term technical resistance.
The biotech sector peaked in 2015. While it bounced back from lows, biotech ETFs give investors exposure to the sector as it recovers.
Both biotech stocks and big pharma stocks involve a different mindset. Treat biotech stocks like options and big pharma stocks like ETFs.
From Talk Markets
The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer